Human oligoclonal recombinant antivenom against the black mamba (Dendroaspis polylepis)

Andreas Hougaard Laustsen, Aneesh Karatt-­Vellatt, Peter Slavny, Alice M. Luther, Majken L. Olesen, Edward W. Masters, Bruno Lomonte, José María Gutiérrez, John McCafferty

    Research output: Contribution to conferencePosterResearchpeer-review

    133 Downloads (Pure)

    Abstract

    Snakebite envenoming is a major cause of death and morbidity in tropical parts of the world. Current therapies are based on animal-­derived antisera that are associated with a high degree of immunogenicity, high cost, and batch-to-batch variation. Here, we report the results of our ongoing efforts of developing the world’s first fully recombinant antivenom based on human IgGs targeting the key toxins from the notorious black mamba (Dendroaspis polylepis).
    Original languageEnglish
    Publication date2016
    Number of pages1
    Publication statusPublished - 2016
    EventPEGS Europe: Protein & Antibody Engineering Summit 2016 - Lisbon, Portugal
    Duration: 31 Oct 20164 Nov 2016

    Conference

    ConferencePEGS Europe: Protein & Antibody Engineering Summit 2016
    CountryPortugal
    CityLisbon
    Period31/10/201604/11/2016

    Fingerprint Dive into the research topics of 'Human oligoclonal recombinant antivenom against the black mamba (<i>Dendroaspis polylepis</i>)'. Together they form a unique fingerprint.

    Cite this